Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics - PubMed (original) (raw)
Affiliations
- PMID: 2151441
Comparative Study
Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics
P E Reynolds et al. Drugs Exp Clin Res. 1990.
Abstract
In this brief review of glycopeptides (teicoplanin and vancomycin) and lipoglycodepsipeptides (ramoplanin), comparison is made of their structure, general mode of action, specific target site and the mechanism by which inhibition of the sensitive enzyme is achieved. Although these two groups of antibiotics are chemically very different, they both inhibit late stages in the biosynthesis of bacterial cell wall peptidoglycan and cause the accumulation of the identical cell wall precursor, UDP-MurNAc-pentapeptide, in the cytoplasm. The specific target site is at the level of the membrane-bound enzymes which catalyse the attachment of wall precursors to a lipid carrier and subsequent polymerisation: ramoplanin inhibits transfer of one of the two precursors, whereas the glycopeptides block polymerisation. As different targets are involved, cross-resistance between glycopeptides and ramoplanin is unlikely and has not yet been reported. The actual mechanisms of action are totally different: glycopeptides inhibit the sensitive reaction by binding firmly, as a result of substantial hydrogen bonding, to acyl-D-Ala-D-Ala termini of the nascent peptidoglycan chains or lipid-linked wall subunits. The substrate is sequestered in a cleft of the antibiotic molecule and cannot interact with the polymerase enzyme. The precise mechanism of action of ramoplanin has not been elucidated, but its action is not dependent on the presence of the acyl-D-Ala-D-Ala group in the substrate and its binding characteristics are different from those of the glycopeptides. It therefore has a different mechanism of action as well as a different site, compared with the glycopeptides.
Similar articles
- Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.
Cudic P, Kranz JK, Behenna DC, Kruger RG, Tadesse H, Wand AJ, Veklich YI, Weisel JW, McCafferty DG. Cudic P, et al. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7384-9. doi: 10.1073/pnas.102192099. Proc Natl Acad Sci U S A. 2002. PMID: 12032292 Free PMC article. - Inhibition of peptidoglycan biosynthesis by ramoplanin.
Somner EA, Reynolds PE. Somner EA, et al. Antimicrob Agents Chemother. 1990 Mar;34(3):413-9. doi: 10.1128/AAC.34.3.413. Antimicrob Agents Chemother. 1990. PMID: 2334153 Free PMC article. - Structure, biochemistry and mechanism of action of glycopeptide antibiotics.
Reynolds PE. Reynolds PE. Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943-50. doi: 10.1007/BF01967563. Eur J Clin Microbiol Infect Dis. 1989. PMID: 2532132 Review. - Extraction and Analysis of Peptidoglycan Cell Wall Precursors.
Binda E, Carrano L, Marcone GL, Marinelli F. Binda E, et al. Methods Mol Biol. 2016;1440:153-70. doi: 10.1007/978-1-4939-3676-2_12. Methods Mol Biol. 2016. PMID: 27311671 - Chemistry and biology of the ramoplanin family of peptide antibiotics.
McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W. McCafferty DG, et al. Biopolymers. 2002;66(4):261-84. doi: 10.1002/bip.10296. Biopolymers. 2002. PMID: 12491539 Review.
Cited by
- A Novel Peptide Antibiotic Produced by Streptomyces roseoflavus Strain INA-Ac-5812 With Directed Activity Against Gram-Positive Bacteria.
Vasilchenko AS, Julian WT, Lapchinskaya OA, Katrukha GS, Sadykova VS, Rogozhin EA. Vasilchenko AS, et al. Front Microbiol. 2020 Sep 15;11:556063. doi: 10.3389/fmicb.2020.556063. eCollection 2020. Front Microbiol. 2020. PMID: 33072016 Free PMC article. - Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.
Riu F, Ruda A, Ibba R, Sestito S, Lupinu I, Piras S, Widmalm G, Carta A. Riu F, et al. Pharmaceuticals (Basel). 2022 Jul 29;15(8):942. doi: 10.3390/ph15080942. Pharmaceuticals (Basel). 2022. PMID: 36015090 Free PMC article. Review. - Treatment options for vancomycin-resistant enterococcal infections.
Linden PK. Linden PK. Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002. Drugs. 2002. PMID: 11827558 Review. - Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.
Cudic P, Kranz JK, Behenna DC, Kruger RG, Tadesse H, Wand AJ, Veklich YI, Weisel JW, McCafferty DG. Cudic P, et al. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7384-9. doi: 10.1073/pnas.102192099. Proc Natl Acad Sci U S A. 2002. PMID: 12032292 Free PMC article. - Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.
Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Cui L, et al. Antimicrob Agents Chemother. 2000 Sep;44(9):2276-85. doi: 10.1128/AAC.44.9.2276-2285.2000. Antimicrob Agents Chemother. 2000. PMID: 10952568 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials